SERODUS ASA appoints scientific advisors for development program in diabetic nephropathy (SER150)
Oslo, Norway, 09 December 2015: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the formation of a new Scientific Advisory Board for the development program in Diabetic Nephropathy.
Serodus CEO, Eva Steiness said: “We are very delighted that Serodus has attracted such a high quality Scientific Advisory Board for the development program in Diabetic Nephropathy. I am confident that its advice and guidance will prove invaluable as the Company advances its development of SER150, a novel treatment for Diabetic Nephropathy. We also do expect to announce scientific advisors for the other programs in the near future.”
The appointed scientific advisors for the development program in Diabetic Nephropathy are:
Prof. George Bakris, University of Chicago, IL, USA
George Bakris, MD, specializes in the diagnosis and reduction of high blood pressure, particularly in complicated and refractory cases. He is also skilled in the treatment of kidney disease, with special expertise in diabetes-related kidney disease.
Prof. Hans-Henrik Parving, Copenhagen University Hospital, Denmark
Dr. Parving has received several national and international awards including the prestigious Castelli Pedroli Prize awarded by the European Association for the Study of Diabetes (1997), and the Novartis Award in Diabetes - long standing achievement (1999) to recognise his accomplishment in pathogenesis, early detection, prevention, and treatment of vascular complications of diabetes mellitus, the 2000 COZAAR Investigator Award for Renal Dysfunction.
Prof. Kristian Rett, Krankenhaus Sachsenhausen, Frankfurt, Germany
Dr. Rett specialize in Endocrinology and is an expert in treatment of diabetes and obesity. He has published in several international journals.
For additional information of a more detail biography of the scientific advisors, please visit www.serodus.com or contact:
CFO, Serodus ASA
Mobile: +47 959 34 199